Blog: ARVINAS, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K) –

Item 7.01 Regulation FD Disclosure.

Arvinas, Inc. (the “Company”) today disclosed top-line results from the Phase 2
cohort expansion portion (VERITAC) of a Phase 1/2 clinical trial with ARV-471, a
novel investigational PROTAC® estrogen receptor (ER) protein degrader. ARV-471
is being co-developed with Pfizer, Inc. for the treatment of patients with
locally advanced or metastatic ER positive / human epidermal growth factor
receptor 2 (HER2) negative (ER+/HER2-) breast cancer.

This disclosure was originally planned for December 8, 2022. However, on
November 21, 2022, the 2022 San Antonio Breast Cancer Symposium (“SABCS”)
incorrectly published for conference participants Arvinas’ and Pfizer’s joint
abstract, omitting a key safety data table, and inadvertently released the
corresponding full data presentation on the SABCS website. These full data were
originally scheduled to be presented in an oral presentation titled “ARV-471, a
PROTAC® estrogen receptor (ER) degrader in advanced ER-positive/human epidermal
growth factor receptor 2 (HER2)-negative breast cancer: phase 2 expansion
(VERITAC) of a phase 1/2 study.”

A copy of the presentation is attached as Exhibit 99.1 to this Current Report
on Form 8-K and is incorporated herein by reference.

The information in this Item 7.01, including Exhibit 99.1, shall not be deemed
“filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as
amended (the “Exchange Act”), or otherwise subject to the liabilities of that
section, nor shall it be deemed incorporated by reference in any filing under
the Securities Act of 1933, as amended, or the Exchange Act, except as expressly
set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

 Exhibit No.                            Description

  99.1           Company Presentation, dated November 21, 2022

104            Cover Page Interactive Data File (formatted as Inline XBRL).


© Edgar Online, source Glimpses

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s